![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/diurnal-ltd-a-neurocrine-biosciences-company-presents-phase-3-extension-study-data-for-modified-release-hydrocortisone-in-patients-with-congenital-adrenal-hyperplasia-at-endo-2023-301849868.html
https://www.fiercepharma.com/pharma/neurocrine-biosciences-doles-out-ps483-acquire-diurnal-group
https://www.proactiveinvestors.com/companies/news/991272/diurnal-shares-rocket-after-knock-out-48mln-bid-from-us-biotech-991272.html
https://www.pharmatimes.com/news/first_adrenal_insufficiency_patient_dosed_in_phase_ii_study_1387551
https://www.investegate.co.uk/diurnal-group-plc--dnl-/rns/commercial-launch-of-efmody-in-the-uk/202109130700074819L/
http://www.pharmatimes.com/news/mhra_authorises_diurnals_cah_therapy_efmody_1372570